fludarabine has been researched along with Cystitis in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Björklund, A; Garming-Legert, K; Hassan, M; Ljungman, P; Mattsson, J; Remberger, M; Serafi, IE; Sundin, M; Törlen, J | 1 |
Al-Ahmari, A; Al-Jefri, A; Al-Musa, A; Al-Seraihy, A; Ayas, M; El-Solh, H; Khairy, A; Markiz, S; Shahin, H; Siddiqui, K | 1 |
Gupta, V; Hamad, N; Kim, DD; Kuruvilla, J; Lipton, JH; Messner, HA; Michelis, FV; Seftel, M; Shanavas, M; Uhm, J | 1 |
Daly, A; Geddes, M; Lam, W; Li, H; Storek, J | 1 |
Al-Ahmari, A; Al-Jefri, A; Al-Seraihi, A; Aldali, A; Ayas, M; El-Solh, H; Khairy, A; Markiz, S; Siddiqui, K | 1 |
Fujioka, T; Hirabayashi, N; Ikegame, K; Kawakami, M; Murakami, M; Ogawa, H; Soma, T; Sugiyama, H; Takahashi, R; Takimoto, T; Tamaki, H | 1 |
Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
1 review(s) available for fludarabine and Cystitis
Article | Year |
---|---|
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
6 other study(ies) available for fludarabine and Cystitis
Article | Year |
---|---|
Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cystitis; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Infant; Male; Middle Aged; Transplantation Conditioning; Vascular Diseases; Vidarabine | 2017 |
Factors affecting the outcome of related allogeneic hematopoietic cell transplantation in patients with Fanconi Anemia.
Topics: Adolescent; Carcinoma, Squamous Cell; Child; Child, Preschool; Cyclophosphamide; Cystitis; Fanconi Anemia; Female; Gamma Rays; Hematopoietic Stem Cell Transplantation; Hemorrhage; Histocompatibility Testing; Humans; Infant; Male; Myeloablative Agonists; Oropharyngeal Neoplasms; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2014 |
The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD.
Topics: Adolescent; Adult; Aged; BK Virus; Busulfan; Cystitis; Cytomegalovirus Infections; Female; Graft vs Host Disease; HLA Antigens; Humans; Male; Middle Aged; Multivariate Analysis; Polyomavirus Infections; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Viremia; Young Adult | 2014 |
Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
Topics: Antilymphocyte Serum; BK Virus; Busulfan; Case-Control Studies; Cystitis; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Length of Stay; Male; Middle Aged; Myeloablative Agonists; Polyomavirus Infections; Recurrence; Risk Factors; Sex Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2017 |
The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
Topics: Adolescent; Antilymphocyte Serum; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cystitis; Disease-Free Survival; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Infant; Male; Prospective Studies; Saudi Arabia; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation.
Topics: Adenoviridae Infections; Adenoviruses, Human; Antilymphocyte Serum; Bronchoalveolar Lavage Fluid; Busulfan; Cystitis; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Count; Lymphocyte Subsets; Male; Methylprednisolone; Middle Aged; Pneumonia, Viral; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |